Fetzima (Levomilnacipran HCl) Patent Expiration, LOE Window & CMS Spending

Fetzima (Levomilnacipran HCl) by AbbVie: FDA Orange Book core substance LOE 2032-05-23, 1 AB generics, $39.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN204168 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-05-23
Last Listed Patent or Exclusivity Date2032-05-23
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$39.1M
2024 Medicare Part D Spend$27.1M
2024 Medicaid Spend$12.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.